Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of EUR2.83, EUR1.32 better than the analyst estimate of EUR1.51. Revenue for the quarter came in at EUR339.28 million versus the consensus estimate of EUR326.45 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.